Axol Bioscience

Axol Bioscience is a provider of human induced pluripotent stem cell (iPSC) technology for drug discovery and research. The company specializes in the manufacturing of iPSC-derived cells, offering a range of products including neurons, neuroinflammatory cells, muscle cells, and cardiac cells.

Axol Bioscience serves the drug discovery and screening markets, with a focus on neuroscience, immune cell, and cardiac modeling. Its clients are likely pharmaceutical and biotechnology companies, as well as academic and research institutions. The company's business model revolves around providing high-quality, functional iPSC-derived cells and related services to support the development of more human-relevant in vitro disease models. This helps researchers to better understand diseases and develop new treatments. The recent acquisition of Phenocell SAS has expanded Axol's iPSC-derived cell models and service offerings, particularly in the areas of ophthalmology and dermatology.

Keywords: iPSC, drug discovery, neuroscience, cardiac modeling, cell models, in vitro, disease models, biotechnology, pharmaceutical, research.